In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …

Cancer is a leading cause of death worldwide and, despite new targeted therapies and
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …

The remarkable success of immune checkpoint inhibitors demonstrates the potential of
tumour-specific CD8+ T cells to prevent and treat cancer. Although the number of lives …

The programmed cell death protein 1 (PD-1) pathway has received considerable attention
due to its role in eliciting the immune checkpoint response of T cells, resulting in tumor cells …

Cancer immunotherapy can induce long lasting responses in patients with metastatic
cancers of a wide range of histologies. Broadening the clinical applicability of these …

Immunotherapy is proving to be an effective therapeutic approach in a variety of cancers. But
despite the clinical success of antibodies against the immune regulators CTLA4 and PD …

It is now well accepted that many tumors undergo a process of clonal selection which means
that tumor antigens arising at various stages of tumor progression are likely to be …

Transcriptomic signatures designed to predict melanoma patient responses to PD-1
blockade have been reported but rarely validated. We now show that intra-patient …

The immune system deploys a multitude of innate and adaptive mechanisms not only to
ward off pathogens but also to prevent malignant transformation (“immune surveillance”) …

The BRAF inhibitors vemurafenib, dabrafenib and encorafenib are used in the treatment of
patients with BRAF-mutant melanoma. They selectively target BRAF kinase and thus …